Duodenal-type follicular lymphoma (DFL) is a rare subtype classified by the 5th edition of the WHO and international consensus classifications of lymphoid neoplasms, typically presenting as localized disease with favorable outcomes. This multicenter retrospective study examines 53 Brazilian DFL patients with a median age of 58.2 years (33-85), with males comprising 50% ( = 27).
View Article and Find Full Text PDFReceptor-interacting protein 1 (RIP1) is a key regulator of multiple signaling pathways that mediate inflammatory responses and cell death. RIP1 kinase activity mediates apoptosis and necroptosis induced by tumor necrosis factor (TNF)-α, Toll-like receptors, and ischemic tissue damage. RIP1 has been implicated in several human pathologies and consequently, RIP1 inhibition may represent a therapeutic approach for diseases dependent on RIP1-mediated inflammation and cell death.
View Article and Find Full Text PDFThis observational, multicenter study aimed to report the clinical evolution of COVID-19 in patients with chronic myeloid leukemia in Latin America. A total of 92 patients presented with COVID-19 between March and December 2020, 26% of whom were severe or critical. The median age at COVID-19 diagnosis was 48 years (22-79 years), 32% were 60 years or older, and 61% were male.
View Article and Find Full Text PDFThis paper proposes a framework based on the principle to understand how the healthcare ecosystem is facing the challenges posed by the COVID-19 by using the Internet of Things (IoT) combined with other digital technologies. The underlying assumption is to consider the Healthcare ecosystem as a collective intelligence system in which the multitude of actors can be coordinated to address the pandemic-specific management challenges. The Italian healthcare ecosystem is analyzed as scenario taking in consideration the 'genes' of the collective intelligence: and Our analysis introduces policy implications based on a unique decision support system (DSS) to allocate a limited set of IoT devices to a larger group of patients, to balance the alternative needs to improve the conditions of the most severe patients but to maximize the efficiency of device use.
View Article and Find Full Text PDFActivation of systemic immune responses using PD-1 checkpoint inhibitors is an essential approach to cancer therapy. Yet, the extent of benefit relative to risk of immune related adverse events (irAE) varies widely among patients. Here, we study endocrine irAE from 7 clinical trials across 6 cancers where atezolizumab (anti-PD-L1) was combined with chemotherapies and compared to standard of care.
View Article and Find Full Text PDF